REQUIMTE/Department of Chemistry and Biochemistry, University of Porto, 4169-007 Porto, Portugal.
Eur J Pharm Sci. 2012 Aug 30;47(1):273-9. doi: 10.1016/j.ejps.2012.04.012. Epub 2012 Apr 17.
The discovery of new and more efficient anti-cancer chemotherapies is a field of research in expansion and growth. Breast cancer (BC) is one of the most studied cancers because it is the principal cause of cancer deaths in women. In the active area for the search of more potent anti-BC drugs, the use of approaches based on Chemoinformatics has played a very important role. However, until now there is no methodology able to predict anti-BC activity of compounds against more than one BC cell line, which should constitute a greater interest. In this study we introduce the first chemoinformatic multi-target (mt) approach for the in silico design and virtual screening of anti-BC agents against 13 cell lines. Here, an mt-QSAR discriminant model was developed using a large and heterogeneous database of compounds. The model correctly classified 88.47% and 92.75% of active and inactive compounds respectively, in training set. The validation of the model was carried out by using a prediction set which showed 89.79% of correct classification for active and 92.49% for inactive compounds. Some fragments were extracted from the molecules and their contributions to anti-BC activity were calculated. Several fragments were identified as potential substructural features responsible for anti-BC activity and new molecules designed from those fragments with positive contributions were suggested as possible potent and versatile anti-BC agents.
新的、更有效的抗癌化疗药物的发现是一个不断发展和增长的研究领域。乳腺癌 (BC) 是研究最多的癌症之一,因为它是女性癌症死亡的主要原因。在寻找更有效的抗乳腺癌药物的活跃领域,基于 chemoinformatics 的方法的应用发挥了非常重要的作用。然而,到目前为止,还没有一种方法能够预测化合物对超过一种乳腺癌细胞系的抗乳腺癌活性,这应该是更大的兴趣所在。在这项研究中,我们引入了第一个 chemoinformatic 多靶(mt)方法,用于设计和虚拟筛选针对 13 种细胞系的抗乳腺癌药物。在这里,使用一个大型的、异构的化合物数据库,开发了一个 mt-QSAR 判别模型。该模型在训练集中分别正确地对 88.47%和 92.75%的活性和非活性化合物进行了分类。通过使用一个预测集来验证模型,该预测集对活性化合物的正确分类率为 89.79%,对非活性化合物的正确分类率为 92.49%。从分子中提取了一些片段,并计算了它们对抗乳腺癌活性的贡献。确定了一些片段作为潜在的负构特征,负责抗乳腺癌活性,并建议从具有正贡献的这些片段设计新的分子,作为可能的有效和多功能的抗乳腺癌药物。